Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis.

Abstract:

OBJECTIVES:Eosinophils possess pro-inflammatory functions in asthma. However, our recent studies have suggested that innate lymphoid cells type 2 (ILC2s) and eosinophils have proresolving properties in rheumatoid arthritis (RA). Nothing is known yet about the mechanisms determining the double-edged role of eosinophils. Therefore, we investigated whether asthma, a paradigm eosinophilic disease, can elicit resolution of chronic arthritis. METHODS:Ovalbumin-triggered eosinophilic asthma was combined with K/BxN serum-induced arthritis, where lung and synovial eosinophil subsets were compared by single-cell RNA sequencing (scRNA-seq). To investigate the involvement of the ILC2-interleukin-5 (IL-5) axis, hydrodynamic injection (HDI) of IL-25 and IL-33 plasmids, IL-5 reporter mice and anti-IL-5 antibody treatment were used. In patients with RA, the presence of distinct eosinophil subsets was examined in peripheral blood and synovial tissue. Disease activity of patients with RA with concomitant asthma was monitored before and after mepolizumab (anti-IL-5 antibody) therapy. RESULTS:The induction of eosinophilic asthma caused resolution of murine arthritis and joint tissue protection. ScRNA-seq revealed a specific subset of regulatory eosinophils (rEos) in the joints, distinct from inflammatory eosinophils in the lungs. Mechanistically, synovial rEos expanded on systemic upregulation of IL-5 released by lung ILC2s. Eosinophil depletion abolished the beneficial effect of asthma on arthritis. rEos were consistently present in the synovium of patients with RA in remission, but not in active stage. Remarkably, in patients with RA with concomitant asthma, mepolizumab treatment induced relapse of arthritis. CONCLUSION:These findings point to a hitherto undiscovered proresolving signature in an eosinophil subset that stimulates arthritis resolution.

journal_name

Ann Rheum Dis

authors

Andreev D,Liu M,Kachler K,Llerins Perez M,Kirchner P,Kölle J,Gießl A,Rauber S,Song R,Aust O,Grüneboom A,Kleyer A,Cañete JD,Ekici A,Ramming A,Finotto S,Schett G,Bozec A

doi

10.1136/annrheumdis-2020-218902

subject

Has Abstract

pub_date

2020-11-04 00:00:00

eissn

0003-4967

issn

1468-2060

pii

annrheumdis-2020-218902

pub_type

杂志文章
  • Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis.

    abstract:BACKGROUND:Anti-citrullinated protein antibodies (ACPAs) are the hallmark of rheumatoid arthritis (RA). Protein citrullination is believed to drive autoantigen selection in RA. Nonetheless, several autoantigens in RA are targeted as native (unmodified) proteins. Here, the study of hnRNP A2/B1 (RA33) provides a framewor...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/annrheumdis-2015-208529

    authors: Konig MF,Giles JT,Nigrovic PA,Andrade F

    更新日期:2016-11-01 00:00:00

  • Association of the oestrogen receptor alpha gene polymorphisms with disease onset in systemic lupus erythematosus.

    abstract:OBJECTIVE:To evaluate the genetic influence of PvuII and XbaI polymorphisms of oestrogen receptor alpha (ORalpha) in patients with systemic lupus erythematosus (SLE) in Korea. METHODS:Genomic DNA from 268 female controls and 137 female SLE patients (41 childhood onset and 96 adult onset) were analysed using PvuII and ...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.2003.012583

    authors: Lee YJ,Shin KS,Kang SW,Lee CK,Yoo B,Cha HS,Koh EM,Yoon SJ,Lee J

    更新日期:2004-10-01 00:00:00

  • Treatment with cimetidine of atypical fasciitis panniculitis syndrome.

    abstract::Three patients presented with septal fasciitis and panniculitis, associated with clinical and laboratory features which precluded straight-forward classification into eosinophilic fasciitis, localised scleroderma, or lupus erythematosus profundus. Treatment with cimetidine caused the remission of cutaneous manifestati...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.49.10.788

    authors: Naschitz JE,Yeshurun D,Rosner I,Abrahamson JE,Misselevitch I,Boss JH

    更新日期:1990-10-01 00:00:00

  • Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis.

    abstract:OBJECTIVE:To evaluate the effects of infliximab and corticosteroid treatment on the lipid profile in patients with active rheumatoid arthritis (RA). METHODS:Infliximab infusions were given at weeks 0, 2, 6 and then every 8 weeks. Before each infusion, disease activity parameters (Disease Activity Index 28-Joint Score ...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.2006.059691

    authors: Peters MJ,Vis M,van Halm VP,Wolbink GJ,Voskuyl AE,Lems WF,Dijkmans BA,Twisk JW,de Koning MH,van de Stadt RJ,Nurmohamed MT

    更新日期:2007-07-01 00:00:00

  • Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass.

    abstract:OBJECTIVES:To determine the prevalence and clinical associations of autoantibodies to myeloperoxidase (MPO) in an unselected series of well-characterised outpatients with rheumatoid arthritis (RA) and to compare the distribution of IgG subclasses of anti-MPO antibodies in these patients with that in patients with syste...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.53.1.24

    authors: Cambridge G,Williams M,Leaker B,Corbett M,Smith CR

    更新日期:1994-01-01 00:00:00

  • Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice.

    abstract:OBJECTIVES:The Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire is a recently developed patient-reported outcome measure (PROM) of disease impact in psoriatic arthritis (PsA). We set out to assess the validity in an independent cohort of patients, estimate the minimally important difference for improvement a...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/annrheumdis-2017-211996

    authors: Holland R,Tillett W,Korendowych E,Cavill C,Waldron N,Brooke M,McHugh NJ

    更新日期:2018-03-01 00:00:00

  • Salivary and serum hyaluronic acid concentrations in patients with Sjögren's syndrome.

    abstract:OBJECTIVE:To evaluate salivary hyaluronic acid (HA) concentration in patients with primary Sjögren's syndrome (SS). METHODS:Salivary and serum HA concentrations were evaluated using a radiometric assay. Thirty nine patients with SS served as the study group and their results were compared with 19 patients having clini...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.57.8.506

    authors: Tishler M,Yaron I,Shirazi I,Yaron M

    更新日期:1998-08-01 00:00:00

  • Advances in interleukin 2 receptor targeted treatment.

    abstract::T cell activation and cellular immune responses are modulated by interleukin 2 (IL2) through binding to its corresponding cell surface receptor. Three forms of the receptor are recognised based on IL2 binding affinity. The high affinity receptor is a heterotrimer composed of alpha, beta, and gamma(c)-polypeptide chain...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章,评审

    doi:10.1136/ard.59.suppl_1.i109

    authors: Morris JC,Waldmann TA

    更新日期:2000-11-01 00:00:00

  • A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.

    abstract::Evidence suggests that endothelin may have a fundamental role in scleroderma pathogenesis, including pulmonary arterial hypertension (PAH)--a leading cause of death in patients with scleroderma. Development of a new class of drug, endothelin receptor antagonists, heralds an improved outlook for patients with scleroder...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章,评审

    doi:10.1136/ard.2003.017673

    authors: Hachulla E,Coghlan JG

    更新日期:2004-09-01 00:00:00

  • Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden.

    abstract:OBJECTIVE:To study prescription patterns of biological treatment in rheumatoid arthritis (RA) patients in southern Sweden, a region with no formal or economic restrictions for the use of biological treatment in rheumatological diseases. Specifically, we studied conformity with the national Swedish guidelines for biolog...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.2007.070714

    authors: Söderlin MK,Geborek P

    更新日期:2008-01-01 00:00:00

  • Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis.

    abstract:OBJECTIVES:Nicotinamide phosphoribosyltransferase (NAMPT)/pre-B-cell colony-enhancing factor/visfatin exerts multiple functions and has been implicated in the pathogenesis of rheumatoid arthritis. To gain insight into its role in arthritis and given that NAMPT is identified as a novel mediator of innate immunity, we ad...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/annrheumdis-2012-202403

    authors: Présumey J,Courties G,Louis-Plence P,Escriou V,Scherman D,Pers YM,Yssel H,Pène J,Kyburz D,Gay S,Jorgensen C,Apparailly F

    更新日期:2013-10-01 00:00:00

  • Measurement of plasma DNA by a physiochemical method: relevance in SLE.

    abstract::Plasma DNA has been measured by a new physiochemical approach based on fluorimetric analysis of phenol extracted nucleic acids electrophoresed on polyacrylamide gels. This method is specific for native double-stranded DNA of molecular weight greater than 5 x 10(6). The use of plasma rigorously freed of leucocytes is e...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.40.6.593

    authors: Klemp P,Meyers OL,Harley EH

    更新日期:1981-12-01 00:00:00

  • Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.

    abstract:OBJECTIVES:There is a lipid paradox in rheumatoid arthritis describing that despite low lipids related to systemic inflammation, there is an increased cardiovascular (CV) risk. Our aim was to evaluate if baseline lipid levels or baseline systemic inflammation were associated with the statin dose sufficient to achieve l...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/annrheumdis-2013-204636

    authors: Rollefstad S,Ikdahl E,Hisdal J,Kvien TK,Pedersen TR,Holme I,Semb AG

    更新日期:2015-08-01 00:00:00

  • The International Classification of Functioning, Disability and Health (ICF) Core Sets for rheumatoid arthritis: a way to specify functioning.

    abstract::Today, patients' functioning is a central issue in medicine. Concepts, classifications, and measurements of functioning and health, such as the International Classification of Functioning, Disability and Health (ICF) are of prime importance in clinical practice, teaching, and research. This report compares the content...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章,评审

    doi:10.1136/ard.2004.028233

    authors: Stucki G,Cieza A

    更新日期:2004-11-01 00:00:00

  • Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.

    abstract:OBJECTIVE:To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of mavrilimumab, a human monoclonal antibody targeting the granulocyte-macrophage colony-stimulating factor receptor-α, in subjects with rheumatoid arthritis (RA). METHODS:A randomised, double-blind, placebo-controlled, dose-e...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1136/ard.2010.146225

    authors: Burmester GR,Feist E,Sleeman MA,Wang B,White B,Magrini F

    更新日期:2011-09-01 00:00:00

  • Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice.

    abstract:BACKGROUND:Population mean changes from clinical trials are difficult to apply to individuals in clinical practice. Responder analysis may be better, but needs validating for level of response and treatment duration. METHODS:The numbers of patients with pain relief over baseline (> or =15%, > or =30%, > or =50%, > or ...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章,meta分析

    doi:10.1136/ard.2009.107805

    authors: Moore RA,Moore OA,Derry S,Peloso PM,Gammaitoni AR,Wang H

    更新日期:2010-02-01 00:00:00

  • Clinical value of gallium-67 scintigraphy in assessment of disease activity in Wegener's granulomatosis.

    abstract:BACKGROUND:Diagnosis of active pulmonary and paranasal involvement in patients with Wegener's granulomatosis (WG) can be difficult. The diagnostic value of gallium-67 scintigraphy in WG is unclear. OBJECTIVE:To evaluate the added diagnostic value of gallium-67 scintigraphy in patients with WG with suspected granulomat...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.62.7.659

    authors: Slart RH,Jager PL,Poot L,Piers DA,Tervaert JW,Stegeman CA

    更新日期:2003-07-01 00:00:00

  • Comparison of rheumatological and gastrointestinal symptoms after infection with Campylobacter jejuni/coli and enterotoxigenic Escherichia coli.

    abstract:OBJECTIVES:To estimate the incidence of postinfectious joint complaints after Campylobacter jejuni/coli enteritis compared with enteritis caused by enterotoxigenic E coli (ETEC). To compare gastrointestinal symptoms, antibiotic treatment, and antibody levels among patients with and without joint symptoms. METHOD:Quest...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.61.5.448

    authors: Locht H,Krogfelt KA

    更新日期:2002-05-01 00:00:00

  • How long should we talk to patients? A study in doctor-patient communication.

    abstract::The 13 questions to which 173 rheumatic outpatients most frequently wished to know the answer were made the basis of a structured interview. Two lengths of interview were conducted in a controlled trial (short being of 2 minutes' duration, long ranging from 4 to 11 minutes). Sixty patients referred directly from their...

    journal_title:Annals of the rheumatic diseases

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1136/ard.41.3.250

    authors: Wright V,Hopkins R,Burton K

    更新日期:1982-06-01 00:00:00

  • Neutropenia during treatment of rheumatoid arthritis with levamisole.

    abstract::Of 60 patients with rheumatoid arthritis treated with levamisole 35% showed a persistent decrease in neutrophil counts from pre-treatment levels and 6 (10%) develped severe neutropenia of less than 1.0 X 10(9)/1. One of these neutropenic patients recoverd without stopping therapy and the other 5 patients recovered rap...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.37.4.366

    authors: Williams GT,Johnson SA,Dieppe PA,Huskisson EC

    更新日期:1978-08-01 00:00:00

  • Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.

    abstract:OBJECTIVES:IKZF1 and IKZF3 (encoding transcription factors Ikaros and Aiolos) are susceptibility loci for systemic lupus erythematosus (SLE). The pharmacology of iberdomide (CC-220), a cereblon (CRBN) modulator targeting Ikaros and Aiolos, was studied in SLE patient cells and in a phase 1 healthy volunteer study. METH...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1136/annrheumdis-2017-212916

    authors: Schafer PH,Ye Y,Wu L,Kosek J,Ringheim G,Yang Z,Liu L,Thomas M,Palmisano M,Chopra R

    更新日期:2018-10-01 00:00:00

  • Pre-ankylosing spondylitis. Histopathological report.

    abstract::A novel explanation for the natural history of joint destruction in the early phase of ankylosing spondylitis is proposed on the basis of the clinical history, x-ray appearance, operative findings, and histopathology of a young patient believed to be suffering from the peripheral form of this disease. ...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.34.1.92

    authors: Pasion EG,Goodfellow JW

    更新日期:1975-02-01 00:00:00

  • The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?

    abstract::Progress in understanding mechanisms of disease are necessary to usher in major changes in treatment. A new era in rheumatoid arthritis (RA) and related chronic autoimmune/inflammatory diseases is now beginning, with a variety of anti-TNFalpha treatments licensed for use in both RA and Crohn's disease. The rationale f...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章,评审

    doi:10.1136/ard.58.2008.i27

    authors: Feldmann M,Bondeson J,Brennan FM,Foxwell BM,Maini RN

    更新日期:1999-11-01 00:00:00

  • Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.

    abstract:OBJECTIVE:The British Society for Rheumatology Biologics Register (BSRBR) has collected data on adverse events including pregnancies in patients with rheumatoid arthritis treated with anti-tumour necrosis factor (anti-TNF) therapy. The purpose of this report is to summarise the pregnancy outcomes in women treated with ...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.2010.140822

    authors: Verstappen SM,King Y,Watson KD,Symmons DP,Hyrich KL,BSRBR Control Centre Consortium, BSR Biologics Register.

    更新日期:2011-05-01 00:00:00

  • A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment.

    abstract:OBJECTIVES:Systemic immunological processes are profoundly shaped by the micro-environments where antigen recognition occurs. Identifying molecular signatures distinctive of such processes is pivotal to understand pathogenic immune responses and manipulate them for therapeutic purposes. Unfortunately, direct investigat...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/annrheumdis-2014-206226

    authors: Spreafico R,Rossetti M,van Loosdregt J,Wallace CA,Massa M,Magni-Manzoni S,Gattorno M,Martini A,Lovell DJ,Albani S

    更新日期:2016-02-01 00:00:00

  • Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.

    abstract:OBJECTIVE:Etanercept monotherapy has been studied and approved for treatment of polyarticular juvenile idiopathic arthritis (JIA). The following study evaluates the safety and efficacy of combination therapy of etanercept and methotrexate compared to etanercept monotherapy in JIA. METHODS:We perfomed an open, non-rand...

    journal_title:Annals of the rheumatic diseases

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1136/ard.2007.087593

    authors: Horneff G,De Bock F,Foeldvari I,Girschick HJ,Michels H,Moebius D,Schmeling H,German and Austrian Paediatric Rheumatology Collaborative Study Group.

    更新日期:2009-04-01 00:00:00

  • Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.

    abstract:OBJECTIVES:To compare the efficacy and safety of lumiracoxib with placebo and celecoxib for osteoarthritis OA in a 13 week, multicentre, randomised, double blind study. METHODS:After a 37 day washout period for nonsteroidal antiinflammatory drugs, 1702 patients with knee OA were randomised to lumiracoxib 200 or 400 mg...

    journal_title:Annals of the rheumatic diseases

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1136/ard.2003.015974

    authors: Tannenbaum H,Berenbaum F,Reginster JY,Zacher J,Robinson J,Poor G,Bliddal H,Uebelhart D,Adami S,Navarro F,Lee A,Moore A,Gimona A

    更新日期:2004-11-01 00:00:00

  • 2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

    abstract:BACKGROUND:Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting t...

    journal_title:Annals of the rheumatic diseases

    pub_type: 共识发展会议,杂志文章,实务指引

    doi:10.1136/annrheumdis-2019-215672

    authors: Hellmich B,Agueda A,Monti S,Buttgereit F,de Boysson H,Brouwer E,Cassie R,Cid MC,Dasgupta B,Dejaco C,Hatemi G,Hollinger N,Mahr A,Mollan SP,Mukhtyar C,Ponte C,Salvarani C,Sivakumar R,Tian X,Tomasson G,Turesson C,S

    更新日期:2020-01-01 00:00:00

  • A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population.

    abstract:OBJECTIVES:Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines. Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but thei...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1136/ard.2007.085704

    authors: Shimane K,Kochi Y,Yamada R,Okada Y,Suzuki A,Miyatake A,Kubo M,Nakamura Y,Yamamoto K

    更新日期:2009-03-01 00:00:00

  • Indomethacin serum concentrations in man. Effects of dosage, food, and antacid.

    abstract::In the use of anti-inflammatory compounds, sustained serum levels are thought to be related to drug efficacy. This study shows that frequent clinical administration of indomethacin can result in sustained serum levels of the drug and that food and antacid may have important modifying effects on serum indomethacin conc...

    journal_title:Annals of the rheumatic diseases

    pub_type: 杂志文章

    doi:10.1136/ard.35.4.333

    authors: Emori HW,Paulus H,Bluestone R,Champion GD,Pearson C

    更新日期:1976-08-01 00:00:00